Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 19;10(1):7-9.
doi: 10.1016/j.ekir.2024.11.018. eCollection 2025 Jan.

Anticomplement Therapies for C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis Recurrence - A Dawn of New Hope

Francesco Emma  1 , Priyadarshini John  2
Affiliations
Editorial

Anticomplement Therapies for C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis Recurrence - A Dawn of New Hope

Francesco Emma et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
A simplified view of the complement system indicating the site of action of anticomplement therapies tested in C3G and IC-MPGN. C3G, C3 glomerulopathy; IC-MPGN, immune-complex membranoproliferative glomerulonephritis.
See this image and copyright information in PMC

Comment on

References

    1. Servais A., Frémeaux-Bacchi V., Lequintrec M., et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2007;44:193–199. doi: 10.1136/jmg.2006.045328. - DOI - PMC - PubMed
    1. Bomback A.S., Charu V., Fakhouri F. Challenges in the diagnosis and management of immune complex-mediated membranoproliferative glomerulonephritis and complement 3 glomerulopathy. Kidney Int Rep. 2025;10:17–28. doi: 10.1016/j.ekir.2024.09.017. - DOI
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–S276. doi: 10.1016/j.kint.2021.05.021. - DOI - PubMed
    1. Halfon M., Taffé P., Bucher Ch., et al. Outcome of patients transplanted for C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis. Kidney Int Rep. 2025;10:75–86. doi: 10.1016/j.ekir.2024.10.008. - DOI
    1. Antonucci L., Thurman J.M., Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024;39:1387–1404. doi: 10.1007/s00467-023-06120-8. - DOI - PubMed

LinkOut - more resources